Cellectar Biosciences, Inc.
CLRB
$4.76
$0.061.28%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 45.11% | 60.56% | -4.23% | -10.62% | -48.83% |
| Total Depreciation and Amortization | -6.25% | 8.85% | 51.53% | 82.39% | 74.23% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -147.89% | -169.52% | -123.31% | -73.46% | 68.69% |
| Change in Net Operating Assets | 10.24% | -1,165.32% | -149.65% | -106.20% | -272.38% |
| Cash from Operations | 23.44% | -13.10% | -46.97% | -53.23% | -55.01% |
| Capital Expenditure | 93.24% | 90.67% | 87.94% | 56.70% | -625.60% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 93.24% | 90.67% | 87.94% | 56.70% | -625.60% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -70.34% | -73.71% | 167.71% | 743.45% | 594.95% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -70.34% | -73.71% | 167.71% | 92.63% | 594.95% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -171.58% | -195.53% | 233.22% | 1,171.91% | 205.41% |